The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.
AuteursAgostinetto E, Gentile G, Samy F, Di Cosimo S, Aftimos P, Pondé N, Eiger D, Lambertini M, Cameron D, Kiermaier A, Bailey A, Viale G, Loi S, Piccart M, de Azambuja E
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.
AuteursCurigliano G, O'Shaughnessy J, Bidard FC, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, Carey LA, Okera M, Melo E, Zagouri F, Magallanes-Maciel M, Karadurmus N, Bahadur S, Speck RM, Wang XA, Pradhan K, Macey J, Kitchen H, Fairhurst S, Miller J, Jhaveri KL, Harbeck N
Reply regarding the European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer.
AuteursBrunelli A, Hardavella G, Huber RM, Berghmans T, Frille A, Rodriguez M, Tietzova I, Depypere L, Asteggiano R, Batchelor T, Costantini A, De Ruysscher D, Faivre-Finn C, Ferguson M, Langer D, Marczin N, Novoa N, Pompili C, Rawlinson J, Snoeckx A, van Geffen WH, Williams C, Blum TG
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.
AuteursRobert M, Kotecki N, Gomez-Roca C, Massard C, Postel-Vinay S, Raimbourg J, Brandao M, Korakis I, Rouge TM, Comis S, Imadalou K, Chevalier C, Cordonnier L, Josse C, Teppaz G, Seité M, Durand J, Thepenier V, Mary C, Gauttier V, Derame M, Morello A, Poirier N, Cassier PA
Bcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma.
AuteursMayet A, Parma B, Lécuyer D, Defruit A, Rana S, Bodac A, Demetter P, Denanglaire S, Ireland AS, Brandão M, Berghmans T, Andris F, Goriely S, Perentes JY, Oliver TG, Meylan E
